Accessibility StatementSkip Navigation SALT LAKE CITY, Oct. 30, 2025 /PRNewswire/ --Â Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will host a virtual fireside chat on Wednesday, November 5, 2025 at 11:00 am ET. Join Dwight Egan. CEO of Co-Dx, for an update on the Company's growth initiatives, including its recently announced definitive agreement with ...

Spectral AI Inc. (NASDAQ:MDAI) is one of the best AI stocks to buy under $20. On October 23, the company announced the pricing of a $7.6 million offering to bolster its balance sheet. The raising of additional capital should help support the expansion and development of the company’s DeepView System. Spectral AI Inc. (MDAI) Eyes $7.6M Capital Raise to Accelerate DeepView System Development In the offering, the company is to issue 4 million shares of common stock at $1.90 per share and corresponding warra ...

DALLAS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the pricing of a $7.6 million offering. The offering will provide the Company with additional growth capital for the continued expansion and development of its DeepView® System. The transaction includes the issuance of 4,000,000 shares of its common st ...

交易概述 - Blackstone和TPG同意以高达183亿美元的交易收购医疗诊断公司Hologic [1] - 收购价格为每股76美元现金 对股票最后收盘价有近6%的溢价 [1] - 总潜在支付可能达到每股79美元 包含每股最高3美元的或有价值权 [2] 交易条款细节 - 股东有资格获得每股最高3美元的非交易性权利 取决于其乳腺健康业务在2026和2027财年达到特定全球收入目标 [2] - 交易预计在2026年上半年完成 [3] 市场反应与公司业务 - Hologic股价在盘前交易中上涨超过4% 交易曾短暂暂停 [2] - 公司专注于女性健康诊断 包括乳腺癌和宫颈癌筛查以及传染病检测 [2] 公司财务状况 - 公司分子诊断业务呈现稳定增长 并报告了乐观的财务业绩 [3] - 但公司指出其乳腺健康部门持续疲软 [3]

Accessibility StatementSkip Navigation "The Nu.Q®Â Vet Cancer Test is intended for use during regular preventive check-ups of older dogs (seven years and older) or for younger dogs of high-risk breeds and we were delighted to offer the Nu.Q® Test to our crisis response canines at our annual meeting. "Providing this additional screening tool allows our HOPE AACR dogs to continue to help people in their time of need." Dr. Tom Butera, Chief Executive Officer, Volition Veterinary , added: "We were delighted to ...

*The Co-Dx PCR platform (including the Co-Dx PCR Homeâ"¢, Co-Dx PCR Proâ"¢, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. Accessibility StatementSkip Navigation New device has the potential to help empower decentralized PCR testing in nearly 30,000 primary health centers across India, advancing efforts to improve availability of life-saving TB diagnostics SALT LAKE CITY, Oct. 16, 2025 /PRNewswire/ -- Co-Diagno ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November 4, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and wi. ...

Reported Improved Gross Margin from Contribution from Higher-Margin Product MixOperating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s Ongoing Focus on Cost Reduction and Operational EfficiencyEarnings per Share $0.00, Compared to a Net Loss of $0.08 per Share in the First Quarter of the Prior Fiscal Year. IRVINE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), ("Biomerica" or the "Company") a global provider of advan ...

融资活动概述 - 公司于2025年10月10日完成一项非公开发行，发行了2,250,000股普通股（或其替代的预融资认股权证）以及可认购最多4,500,000股普通股的F系列认股权证，发行价格为每股2.00美元 [1] - F系列认股权证的行权价为每股1.75美元，可立即行使，有效期为发行日后五年半 [1] - 本次发行的总收益（扣除费用前）为450万美元 [2] 资金用途与业务重点 - 发行净收益计划用于获取FDA批准相关事宜（包括相关临床研究）、其他研发活动以及一般营运资金需求 [2] - 公司专注于通过其Symphony系统改善患者预后，该系统是一种经济高效、快速的近患者检测系统，用于脓毒症分诊和疾病进展监测 [5] - 公司的首个候选产品是用于脓毒症的IL-6检测，旨在提供约20分钟的“样本到结果”检测，以帮助医疗专业人员更早做出更好的分诊/治疗决策 [5] 发行相关安排 - Rodman and Renshaw LLC担任此次发行的独家配售代理 [2] - 本次发行依据1933年证券法第4(a)(2)条和/或D条例进行，所发行证券及认股权证对应的普通股未根据证券法或适用的州证券法进行注册 [3] - 根据与投资者签订的注册权协议，公司同意提交一份涵盖上述证券的转售注册声明 [3]

融资交易概述 - 公司宣布达成最终协议，进行私募配售，内容包括出售2,250,000股普通股（或其预融资认股权证）以及可购买最多4,500,000股普通股的F系列认股权证，购买价格为每股2.00美元 [1] - 此次私募配售按纳斯达克规则的市价定价，F系列认股权证行权价为每股1.75美元，发行后可立即行权，有效期为发行日后5.5年 [1] - 该私募配售预计于2025年10月10日左右完成，需满足惯例交割条件 [1] 融资规模与用途 - 本次发行预计总收益为450万美元，需扣除配售代理费用及公司承担的其他发行费用 [2] - 公司拟将发行净收益用于获取FDA批准相关事宜（包括相关临床研究）、其他研发活动以及一般营运资金需求 [2] 证券发行法律细节 - 本次发行证券依据《1933年证券法》第4(a)(2)条及/或D条例进行私募，证券及认股权证对应的普通股均未根据证券法或适用的州证券法进行注册 [3] - 根据与投资者签订的注册权协议，公司同意提交涵盖上述证券的转售注册声明 [3] 公司业务介绍 - 公司是一家医疗诊断公司，专注于通过其Symphony系统改善患者预后，该系统是一种经济高效、快速的近患者检测系统，用于脓毒症分诊和疾病进展监测 [5] - 公司的首个候选产品是用于脓毒症的IL-6检测，旨在提供从“样本到结果”约20分钟的准确可靠结果，以帮助医疗专业人员更早、更好地做出分诊/治疗决策 [5]